Tasquinimod is an allosteric modulator of HDAC4 survival signaling within the compromised cancer microenvironment

Cancer Research

Volumn 73, Issue 4, 2013, Pages 1386-1399

  Isaacs, John T ^a,b   Antony, Lizamma ^b   Dalrymple, Susan L ^b   Brennen, W Nathaniel ^c   Gerber, Stephanie ^a   Hammers, Hans ^a   Wissing, Michel ^b   Kachhap, Sushant ^b   Luo, Jun ^a   Xing, Li ^a,d   Bjork, Per ^d   Olsson, Anders ^b,c   Bjork, Anders ^e   Leanderson, Tomas ^d,e  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c PFIZER INC   (United States)

^d Active Biotech Research AB   (Sweden)

^e LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

G 202; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 4; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PRODRUG; TASQUINIMOD; THAPSIGARGIN PRODRUG; UNCLASSIFIED DRUG; ZINC ION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLADDER TUMOR; BREAST TUMOR; CANCER CELL; CANCER CONTROL; CELL SURVIVAL; CELL TRANSFORMATION; COLON TUMOR; CONTROLLED STUDY; DEACETYLATION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG STRUCTURE; DRUG TARGETING; ENDOTHELIUM CELL; ENHANCER REGION; EPIGENETICS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; METAL BINDING; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN LOCALIZATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ACETYLATION; ALLOSTERIC REGULATION; ANIMALS; BLOTTING, WESTERN; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; HISTONE DEACETYLASES; HISTONES; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; MICE, NUDE; MODELS, MOLECULAR; NEOPLASMS; PRODRUGS; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; QUINOLINES; REPRESSOR PROTEINS; RNA INTERFERENCE; SIGNAL TRANSDUCTION; THAPSIGARGIN; TUMOR MICROENVIRONMENT; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84874342427     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2730     Document Type: Article

References (50)

1. Pili R, Haggman M, Stadler W, Gingrich JR, Assikis VJ, Bjork A, et al. A randomized multicenter international phase II study of tasquinimod in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:75.
2. Isaacs JT. The long and winding road for the development of tasquinimod as an oral second-generation quinoline-3-carboxamide antiangiogenic drug for the treatment of prostate cancer. Expert Opin Investig Drugs 2010;19:1235-43.
3. Isaacs JT, Pili R, Qian DZ, Dalrymple SL, Garrison JB, Kyprianou N, et al. Identification of ABR-215050 as lead second generation quinoline- 3-carboxamide anti-angiogenic agent for the treatment of prostate cancer. Prostate 2006;66:1768-78. (Pubitemid 44893902)
4. Dalrymple SL, Becker RE, Isaacs JT. The quinoline-3-carboxamide anti-angiogenic agent, tasquinimod, enhances the anti-prostate cancer efficacy of androgen ablation and taxotere without effecting serum PSA directly in human xenografts. Prostate 2007;67:790-7.
5. Olsson A, Bjork A, Vallon-Christersson J, Isaacs JT, Leanderson T. Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer 2010;9:107.
6. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT. Tasquinimod prevents the angiogenic rebound induced by fractionated radiation resulting in an enhanced therapeutic response of prostate cancer xenografts. Prostate 2012;72:638-48.
7. Kallberg E, Vogl T, Liberg D, Olsson A, Bjork P, Wilkstrom P, et al. S100A9 interaction with TLR4 promotes tumor growth. PLoS One 2012;7:e34207.
8. Lunt SJ, Chaudary N, Hill RP. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009;26:19-34.
9. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86:353-64. (Pubitemid 26272076)
10. Jennbacken K, Welen K, Olsson A, Axelsson B, Torngren M, Damber JE, et al. Inhibition of metastasis in a castration resistant prostate cancer model by quinoline-3-carboxamide tasquinimod (ABR- 215050). Prostate 2012;72:913-24.
11. Nakatsu MN, Sainson RC, Aoto JN, Aikenhead M, Perez-del-Pulgar S, Carpenter PM, et al. Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothetial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. Microvasc Res 2003;66:102-12. (Pubitemid 36962872)
12. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, et al. Engineering a prostate-specific membrane antigen- activated tumor endothelial cell prodrug for cancer therapy. Sci Trans Med 2012;4:140-54.
13. Litvinov IV, Vander Griend DJ, Xu Y, Antony L, Dalrymple SL, Isaacs JT. Low-calcium serum-free defined medium selects for growth of normal prostatic epithelial stem cells. Cancer Res 2006;66:8598-607. (Pubitemid 44449174)
14. Fischle W, Dequiedt F, Hendzel MJ, Guenther MG, Lazar MA, Voelter W, et al. Enzymatic activity associated with class II HDACs is dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol Cell 2002;9:45-57 (Pubitemid 34127770)
15. Lahm A, Paolini C, Pallaoro M, Jones P, Neddermann P, Sambucini S, et al. Unraveling the hidden catalytic activity of vertebrate class IIa histone deacetylases. Proc Natl Acad Sci USA 2007;104: 17335-40. (Pubitemid 350219843)
16. Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A, et al. Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol 2009;7:e97.
17. Bottomley MJ, Surdo PL, Di Giovine P, Cirillo A, Scarpelli R, Ferrigno F, et al. Structural and functional analysis of the human HDAC4 catalytic domain reveals a regulatory structural zinc-binding domain. J Biol Chem 2008;283:26694-704.
18. Raman V, Artemov D, Pathak AP,Winnard PT, McNutt S, Yudina A, et al. Characterizing vascular parameters in hypoxic regions: a combination magnetic resonance and optical imaging study of a human prostate cancer model. Cancer Res 2006;66: 9929-36. (Pubitemid 44672045)
19. Semenza GL, Jiang BH, Leung SW, Passantino R, Concordet JP, Maire P, et al.Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1. J Biol Chem 1996;271: 32529-37.
20. Prakash K, Pirozzi G, Elashoff M, Munger W, Waga I, Dhir R, et al. Symptomatic and asymptomatic benign prostatic hyperplasia: molecular differentiation by using microarrays. Proc Natl Acad Sci U S A 2002;99:7598-603. (Pubitemid 34568737)
21. Liu W, Laitinen S, Vihinen M, Kowalski J, Yu G, Chen L, et al. Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer. Nat Med 2009;15:559-65.
22. Dunn TA, Chen S, Faith DA, Hicks JL, Platz EA, Chen Y, et al. A novel role of myosin VI in human prostate cancer. Am J Pathol 2006;169: 1843-54. (Pubitemid 351182013)
23. Denko N, Wernke-Dollries K, Johnson AB, Hammond E, Chiang CM, Barton MC. Hypoxia actively represses transcription by inducing negative cofactor 2 (Dr1/DrAP1) and blocking preinitiation complex assembly. J Biol Chem 2003;278:5744-9.
24. Manalo D, Rowan A, Lavoie T, Natarajan L, Kelly BD, Ye SQ, et al. Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1. Blood 2005;105:659-69. (Pubitemid 40070750)
25. Johnson AB, Denko N, Barton MC. Hypoxia induces a novel signature of chromatin modifications and global repression of transcription. Mut Res 2008;640:174-9.
26. Li Q, Costa M. c-Myc mediates a hypoxia-induced decrease in acetylated histone H4. Biochimie 2009;91:1307-10.
27. Haberland M, Montgomery RL, Olson ER. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev/Genet 2009;10:32-42.
28. Halkidou K, Cook S, Leung HY, Neal DE, Robson CN. Nuclear accumulation of histone deacetylase 4 (HDAC4) coincides with the loss of androgen sensitivity in hormone refractory cancer of the prostate. Eur Urol 2004;45:382-9.
29. Cadot B, Brunetti M, Coppari S, Fedeli S, de Rinaldis E, Dello Russo C, et al. Loss of histone deacetylase 4 causes segregation defects during mitosis of p53-deficient human tumor cells. Cancer Res 2009;69: 6074-82.
30. Geng H, Harvey CT, Pittsenbarger J, Liu Q, Beer TM, Xue C, et al. HDAC4 protein regulates HIF-1a protein lysine acetylation and cancer cell response to hypoxia. J Biol Chem 2011;286: 38095-102.
31. Martin M, Kettmann R, Dequiedt F. Class IIa histone deacetylases: regulating the regulators. Oncogene 2007;26:5450-67. (Pubitemid 47255927)
32. Kato H, Tamamizu-Kato S, Shibasaki F. Histone Deacetylase 7 associates with hypoxia-induced factor-1a and increases transcriptional activity. J Biol Chem 2004;279:41966-74. (Pubitemid 39313647)
33. Ellis L, Hammers H, Pili R. Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 2009;280:145-53.
34. Seo HW, Kim EJ, Na H, Lee MO. Transcriptional activation of hypoxia-inducible factor-1 alpha by HDAC4 and HDAC5 involves differential recruitment of p300 and FIH-1. FEBS Lett 2009;583: 55-60.
35. Xenaki G, Ontikatze T, Rajendran R, Stratford IJ, Dive C, Krstic- Demonacos M, et al. PCAF is an HIF-1a cofactor that regulates p53 transcriptional activity in hypoxia. Oncogene 2008;27:5785-96.
36. Lim JH, Lee YM, Chun YS, Chen J, Kim JE, Park JW. Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxiainduced factor 1a. Mol Cell 2010;38:864-78.
37. Michel G, Minet E, Mottet D, Remacle J, Michiels C. Site-directed mutagenesis of the hypoxia-induced factor-1a DNA-binding domain. Biochim Biophys Acta 2002;1578:73-83. (Pubitemid 35223458)
38. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 Mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1a (HIF-1a) and enhance the transcriptional activity of HIF-1a. J Biol Chem 1999;274:32631-7.
39. Liu R, Wang L, Chen G, Katoh H, Chen C, Liu Y, et al. FOXP3 upregulates p21 expression by site-specific inhibition of histone deacetylase 2/histone deacetylatase 4 association to the locus. Cancer Res 2009;69:2252-9.
40. Mottet D, Pirotte S, Lamour V, Hagedorn M, Javerzat S, Bikfalvi A, et al. HDAC4 represses p21WAF1/Cip1 expression in human cancer cells through a Sp1-dependent, p53-independent mechanism. Oncogene 2009;28:243-56.
41. Baumeister P, Dong D, Fu Y, Lee AS. Transcriptional induction of GRP78/BiP by histone deacetylase inhibitors and resistance to histone deacetylase inhibitor-induced apoptosis. Mol Cancer Ther 2009;8: 1086-94.
42. Halili M, Andrews MR, Labzin LI, Schroder K, Matthias G, Cao C, et al. Differential effects of selectiveHDACinhibitors on macrophage inflammatory responses to the Toll-like receptor 4 agonist LPS. J Leukoc Biol 2010;87:1103-14.
43. Wang X, Li G, Wang A, Zan Z, Merchan JR, Halmos B. Combined histone deacetylase and cyclooxigenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinogenesis. 2012. Epub ahead of print].
44. Urbich C, Rossig L, Kaluza D, Potent M, Boeckel JN, Knau A, et al. Hdac5 is a repressor of angiogenesis and determines the angiogenic gene expression pattern of endothelial cells. Blood 2009;113:5669-79.
45. Stronach EA, Alfraidi A, Rama N, Datler C, Studd JB, Agarwal R, et al. HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. Cancer Res 2011;71:4412-22.
46. Chu F, Chou P, Mirkin BL, Mousa SA, Rebbaa A. Cellular conditioning with trichostatin A enhances the anti-stress response through upregulation of HDAC4 and down-regulation of the IGF/Akt pathway. Aging Cell 2008;7:516-25. (Pubitemid 351998612)
47. Zhao F, Hoechst B, Duffy A, Gamrekelashvili J, Fiorvanti S, Manns MP, et al. S100A9 a new marker for monocytic human myeloid-derived suppressor cells. Immunol 2012;136:176-83.
48. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4. J Leukoc Biol 2009;85: 996-1004.
49. Corzo CA, Condamine T, Lu L, Cotter MJ, Youn JI, Cheng P, et al. HIF- 1a regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 2010;207; 2439-53.
50. Squadrito ML, De Palma M. Macrophage regulation of tumor angiogenesis: implications for cancer therapy. Mol Aspects Med 2011;32: 123-45.